Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Oct 06, 2022
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Oct 05, 2022
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences Oct 04, 2022
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer Oct 03, 2022
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA Sep 22, 2022
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Sep 08, 2022
